- EMVision Medical Devices (EMV) completes enrolment of around half the 30 participants required for its stage one clinical trial for stroke monitoring
- The company told investors its pre-validation phase of the clinical trial is on schedule, with roughly half of the healthy participants for stage one now enlisted
- It’s anticipated the company will have registered all 30 participants within the coming weeks, at which point stage two of the trial will be activated, involving up to 150 acute stroke patients
- Meanwhile, the company achieved a technical development milestone for its portable imaging devices under the Commonwealth of Australia Medical Research Future Fund (MRFF) program in partnership with the Australian Stroke Alliance (ASA), triggering a $600,000 milestone payment from the ASA
- EMVision is up 3.53 per cent, trading at $1.76 at 12:25 pm AEDT
EMVision Medical Devices (EMV) has enrolled around half of the 30 participants required for its stage one clinical trial for stroke monitoring.
The company told investors its pre-validation phase of the clinical trial is on schedule, with roughly half of the healthy participants for stage one now enrolled.
It’s anticipated the company will have registered all 30 participants within the coming weeks, at which point stage two of the trial will be activated, involving up to 150 acute stroke or stroke mimic patients.
“We are pleased that our trial is progressing as planned, especially given it commenced just before the holiday period,” EMVision CEO Dr Ron Weinberger said.
The company’s device for monitoring stroke has been noted as having an “ease of use” by operators and comfort for participants, while no device-related adverse events have been reported.
Meanwhile, the company has also achieved a technical development milestone for its portable imaging devices under the Commonwealth of Australia Medical Research Future Fund (MRFF) program in partnership with the Australian Stroke Alliance (ASA). This has triggered a $600,000 milestone payment from the ASA.
The milestone activities focused on extensive benchtop, or phantom brain and complex simulation experiments designed to mimic clinical use of the EMVision technology to support stroke subtype diagnosis.
Both the existing first gen system and the second gen road and air ambulance device, currently under development, demonstrated “high levels” of performance in these experiments.
As a result, a full 3D second gen antenna array has been fabricated for further verification and development, with trials targeted for next year.
“The testing conducted as part of our ASA milestones has shown encouraging benchtop results from our system enhancements which bodes well for our clinical trials,” Dr Ron Weinberger continued.
“We are excited with the progress being made with our 2nd Gen first responder model as well as our 1st Gen in-hospital device.”
EMVision was up 3.53 per cent, trading at $1.76 at 12:25 pm AEDT.